Response to TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas

Modern Pathology

Volumn 22, Issue 10, 2009, Pages 1398-1399

  Esgueva, Raquel ^a   Demichelis, Francesca ^a   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

CANCER DIAGNOSIS; CANCER GROWTH; FOLLOW UP; FUSION GENE; GENE FUSION; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; TMPRSS2 ERG GENE; TRANSURETHRAL RESECTION; WATCHFUL WAITING; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; MALE; NOTE; PAGET NIPPLE DISEASE; PATHOLOGY; PATIENT SELECTION; PROSTATE TUMOR;

CARCINOMA, DUCTAL; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PATIENT SELECTION; PROSTATIC NEOPLASMS;

EID: 70349682886     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.100     Document Type: Letter

References (14)

1. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol 2009;22:359-365.
2. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
3. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45. (Pubitemid 46294173)
4. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
5. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263.
6. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599.
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
8. Ward JF, Blute ML, Slezak J, et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872-1876.
9. Carver BS, Bianco Jr FJ, Scardino PT, et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006;176:564-568.
10. Porter CR, Kodama K, Gibbons RP, et al. 25-year prostate cancer control and survival outcomes: a 40- year radical prostatectomy single institution series. J Urol 2006;176:569-574.
11. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172(4 Pt 1):1297-1301.
12. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599.
13. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
14. Rickman D, Pflueger D, Moss B, et al. SLC45A3-ELK4 is a novel and frequent ETS fusion transcript in prostate cancer. Cancer Res 2009;69:2734-2738.